Pipeline
Trials
People
News
Contact
Contact
News
Button Text
January 20, 2026
Orphai Therapeutics’ Phase 2a LAM-001 Study Selected for Oral Presentation at the American Thoracic Society (ATS) 2026 International Conference
October 2, 2023
Orphai Therapeutics Announces Oral Presentation and Posters at the 22nd Annual NEALS Conference
August 31, 2023
AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)
August 18, 2023
AI Therapeutics Announces Investigator Initiated Phase 2 Trial at UCSF to Study LAM-001 in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant
AI Therapeutics Announces Initiation of a Phase II Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)
May 9, 2023
AI Therapeutics Announces Poster Presentation at the 2023 American Thoracic Society International Conference
